

04-05-01

A
BOXSEQTO/40/40
USPTO
0

UTILITY PATENT
APPLICATION TRANSMITTAL
(Under 37 C.F.R. §1.53(b))

Docket No.: NV1932

Page 1 of 2

Title IMPROVED METHOD FOR THE PRODUCTION
OF BACTERIAL TOXINS

Express Mail Label No.: EL524824495US

J1044 U.S. PRO
09/09/09
04/04/01

APPLICATION ELEMENTS

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231INVENTORS: Milan S. Blake
John A. Bogdan, Jr.
Javier Nazario-Larrieu

1. <input checked="" type="checkbox"/>	Fee Transmittal Form (Submit an original, and a duplicate for fee processing)	10. <input type="checkbox"/>	Information Disclosure Statement (IDS)/PTO-1449	<input type="checkbox"/>	Copies of IDS Citations
2. <input checked="" type="checkbox"/>	Specification [Total Pages 29]	11. <input type="checkbox"/>	Preliminary Amendment		
3. <input checked="" type="checkbox"/>	Drawing(s) (35 USC §113) [Total Pages (Figs. 1-9) 13]	12. <input checked="" type="checkbox"/>	Return Receipt Postcard (MPEP 503)		
4. <input type="checkbox"/>	Signed Declaration [Total Pages]	13. <input type="checkbox"/>	Small Entity Statement(s)		
a. <input type="checkbox"/>	Newly executed (original or copy)	14. <input type="checkbox"/>	Certified Copy of Priority Documents (s)		
b. <input type="checkbox"/>	Copy from a prior application (37 CFR §1.63(d))	15a. <input type="checkbox"/>	Cancel in the application original claims _____ before calculating the filing fee		
(Note Box 5 below) <u>DELETION OF INVENTOR(S)</u>					
i. <input type="checkbox"/>	Signed statement attached deleting inventor named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b)	15b. <input type="checkbox"/>	Amend the specification by inserting before the first line the sentence: —This is a _____ Continuation, _____ Divisional, _____ Continuation-in-part, of application /_____, filed /_____/_____/____/		
5. <input type="checkbox"/>	Incorporation By Reference (useable if Box 4b is checked.) T entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein	15c. <input type="checkbox"/>	I hereby verify that the attached papers are a true copy of the latest inventor-signed prior application, including a copy of the oath or declaration showing the original signature or an indication it was signed. I hereby verify that the papers are a true copy of the latest signed prior application number /_____, filed /_____/____/ and further that all statements made herein of my own knowledge are true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.		
6. <input checked="" type="checkbox"/>	Nucleotide and/or Amino Acid Sequence Submission	15d. <input type="checkbox"/>	Other _____		
a. <input type="checkbox"/>	Computer Readable Copy	15e. <input type="checkbox"/>	Other _____		
b. <input checked="" type="checkbox"/>	Paper Copy (identical to computer copy)				
c. <input type="checkbox"/>	Statement Verifying identify of above copies				
7. <input type="checkbox"/>	Assignment Papers (cover sheet & document(s))				
8. <input type="checkbox"/>	37 CFR §3.73(b) Statement	<input type="checkbox"/>	Power of Attorney		
9. <input type="checkbox"/>	English Translation Document				
16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:					
<input type="checkbox"/>	Continuation	<input type="checkbox"/>	Divisional	<input type="checkbox"/>	Continuation-in-part (CIP) of prior application No.: _____ / _____

UTILITY PATENT
APPLICATION TRANSMITTAL
(Under 37 C.F.R. §1.53(b))

Docket No.: NV1932

Page 2 of 2


Title IMPROVED METHOD FOR THE PRODUCTION
OF BACTERIAL TOXINS
Express Mail Label No.: EL524824495US

CLAIMS	(1) FOR	(2) NUMBER	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(b))	8-20 =	0	X \$ 18 =	\$0
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	3	0	\$ 80 =	\$0
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR §1.16(d))			+ \$ 270 =	\$ 0
				BASIC FEE (37 CFR §1.16(a))	\$710.00
				TOTAL =	\$710.00

The Commissioner is hereby authorized to credit overpayments or charge the following fees, and any other fees necessary during the pendency of the application, to Deposit Account No. 02 -1437 (Docket NV1932).
(For this purpose, pursuant to 37 CFR §1.136(a)(3) please incorporate the above authorization into any future reply as a petition for an appropriate extension of time if a petition for an extension of time is not otherwise provided.)

- a. Fees required under 37 CFR §1.16
- b. Fees required under 37 CFR §1.17
- c. Fees required under 37 CFR §1.18

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

NAME	C. Joseph Faraci, Reg. No. 32,350
SIGNATURE	
DATE	April 4, 2001

CORRESPONDENCE ADDRESS

Baxter Healthcare Corporation
P.O. Box 15210
Irvine, California 92614
Telephone: (949) 250-6827 Fax: (949) 474-6330

CERTIFICATE OF MAILING UNDER 37C.F.R. §1.10

I hereby certify that the above-identified document is being deposited with the United States Postal Service as Express Mail, Label No. EL524824495US in an envelope addressed to: Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231 on April 4, 2001.

By: 
Diane Branham

CERTIFICATE OF MAILING

Date: April 4, 2001
Express Mailing Label No.: EL52482449SUS

I hereby certify that on the date listed above, this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service in accordance with 37 C.F.R. § 1.10 as "Express Mail Post Office to Addressee," with sufficient postage in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, DC 20231.

Diane Branham

Diane Branham

PATENT

Applicant: Blake, et al.
Serial No.: Not Yet Assigned
Filed: April 4, 2001
Title: **IMPROVED METHOD FOR
THE PRODUCTION OF
BACTERIAL TOXINS**
Examiner: Not Yet Assigned
Group Art Unit: Not Yet Assigned
Atty Docket No.: NV1932

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Submission of "Sequence Listing" and Computer readable Copy for Biotechnology Invention
Containing Nucleotide and/or Amino Acid Sequence (37 CFR §§ 1.821 - 1.825)**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with 37 CFR §§ 1.821-1.825 Applicant encloses a paper copy of the Sequence listing for the nucleotide and amino acid sequences disclosed in the above-identified application. A copy of the Sequence Listing in computer readable form is also submitted herewith.

**Statement That Computer Readable Copy
of Sequence Listing is the Same as
the Paper Copy of the Sequence Listing**

I hereby state:

1. The computer readable form of the Sequence Listing submitted in this application is the same as the paper copy of the "Sequence Listing" to which it is indicated to relate.
2. No new matter has been added to the computer readable copy or the paper copy of this Sequence Listing.

Verification

I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the above-identified patent application and any patent issuing thereon.

Respectfully Submitted,



C. Joseph Faraci
Reg. No. 32,350

Dated: April 4, 2001

Baxter Healthcare Corporation
P.O. Box 15210
Irvine, CA 92623-5210
Telephone: (949) 250-6827
Facsimile: (949) 474-6330